文献速递心脑血管急症

中危患者的外科或经导管主动脉瓣置换术

Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients.
PubMed 文献 · N Engl J Med · 2017-03-17
一句话结论在中危重度症状性主动脉瓣狭窄患者中,自膨胀瓣膜TAVR在24个月全因死亡或致残性卒中复合终点上不劣于外科主动脉瓣置换。

SURTAVI随机试验在87个中心纳入1746例中危重度症状性主动脉瓣狭窄患者,比较自膨胀瓣膜TAVR与外科主动脉瓣置换。1660例尝试了TAVR或外科手术,平均年龄79.8±6.2岁,胸外科医师协会预测死亡风险4.5±1.6%。24个月主要复合终点(全因死亡或致残性卒中)估计发生率TAVR组12.6%、外科组14.0%,差值95%可信区间-5.2%至2.3%,非劣效后验概率>0.999。外科组急性肾损伤、心房颤动和输血需求更高,TAVR组残余主动脉瓣反流和起搏器植入需求更高;TAVR平均跨瓣压差更低、瓣口面积更大,两组24个月均未发生结构性瓣膜退化。

要点

  • 中危重度症状性主动脉瓣狭窄患者24个月全因死亡或致残性卒中:TAVR组12.6% vs 外科组14.0%,差值95%可信区间-5.2%至2.3%,非劣效后验概率>0.999。
  • 外科组急性肾损伤、心房颤动和输血需求高于TAVR组;TAVR组残余主动脉瓣反流和起搏器植入需求高于外科组。
  • TAVR后平均跨瓣压差低于外科、瓣口面积大于外科;两组24个月均未发生结构性瓣膜退化。
  • 该试验使用自膨胀瓣膜行TAVR,对照为外科主动脉瓣置换,人群为胸外科医师协会预测死亡风险4.5±1.6%的中危患者。

适用人群与场景

  • 中危重度症状性主动脉瓣狭窄患者,均接受TAVR或外科主动脉瓣置换尝试,平均年龄79.8±6.2岁,胸外科医师协会预测死亡风险4.5±1.6%。

研究设计与关键结果

  • 随机试验共纳入1746例患者,87个中心,其中1660例尝试了TAVR或外科手术;TAVR采用自膨胀瓣膜。
  • 主要终点为24个月全因死亡或致残性卒中复合终点:TAVR组估计发生率12.6% vs 外科组14.0%,差值95%可信区间-5.2%至2.3%,非劣效后验概率>0.999(贝叶斯分析,界值0.07)。
  • 外科组急性肾损伤、心房颤动和输血需求发生率高于TAVR组;TAVR组残余主动脉瓣反流和起搏器植入需求发生率高于外科组。
  • TAVR后平均跨瓣压差低于外科、主动脉瓣口面积大于外科;24个月结构性瓣膜退化两组均未发生。

证据类型、等级与局限

  • 证据类型:随机对照试验(SURTAVI,ClinicalTrials.gov NCT01586910),由Medtronic资助。
  • 非劣效性采用贝叶斯分析方法,界值0.07;非劣效后验概率>0.999。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在中危重度症状性主动脉瓣狭窄患者中,自膨胀瓣膜TAVR可作为外科主动脉瓣置换的非劣效替代方案,但两种操作的不良事件模式不同。
  • 选择TAVR时需考虑残余主动脉瓣反流和起搏器植入需求较高的风险;选择外科时需考虑急性肾损伤、心房颤动和输血需求较高的风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Although transcatheter aortic-valve replacement (TAVR) is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk.

METHODS: We evaluated the clinical outcomes in intermediate-risk patients with severe, symptomatic aortic stenosis in a randomized trial comparing TAVR (performed with the use of a self-expanding prosthesis) with surgical aortic-valve replacement. The primary end point was a composite of death from any cause or disabling stroke at 24 months in patients undergoing attempted aortic-valve replacement. We used Bayesian analytical methods (with a margin of 0.07) to evaluate the noninferiority of TAVR as compared with surgical valve replacement.

RESULTS: A total of 1746 patients underwent randomization at 87 centers. Of these patients, 1660 underwent an attempted TAVR or surgical procedure. The mean (±SD) age of the patients was 79.8±6.2 years, and all were at intermediate risk for surgery (Society of Thoracic Surgeons Predicted Risk of Mortality, 4.5±1.6%). At 24 months, the estimated incidence of the primary end point was 12.6% in the TAVR group and 14.0% in the surgery group (95% credible interval [Bayesian analysis] for difference, -5.2 to 2.3%; posterior probability of noninferiority, >0.999). Surgery was associated with higher rates of acute kidney injury, atrial fibrillation, and transfusion requirements, whereas TAVR had higher rates of residual aortic regurgitation and need for pacemaker implantation. TAVR resulted in lower mean gradients and larger aortic-valve areas than surgery. Structural valve deterioration at 24 months did not occur in either group.

CONCLUSIONS: TAVR was a noninferior alternative to surgery in patients with severe aortic stenosis at intermediate surgical risk, with a different pattern of adverse events associated with each procedure. (Funded by Medtronic; SURTAVI ClinicalTrials.gov number, NCT01586910 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017. PMID: 28304219. doi:10.1056/NEJMoa1700456

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。